Contact UsCareers
Top bar
WHO WE ARE
  • OUR MISSION
  • MEET OUR TEAM
    •  PIPELINE
  • OUR APPROACH
  • GAMMA SECRETASE INHIBITORS (GSIs)
  • INVESTIGATIONAL THERAPIES: AL101 & AL102
    •  CLINICAL TRIALS
  • CLINICAL PRIVACY NOTICE
    • MEDICAL PROFESSIONALS PATIENTS & CAREGIVERS
  • SCIENCE EXPLAINED
  • PARTICIPATING IN CLINICAL TRIALS
  • EXPANDED ACCESS POLICY
  • PATIENT RESOURCES
    •  INVESTORS & MEDIA
  • NEWS RELEASES
  • EVENTS & PRESENTATIONS
  • FINANCIAL INFORMATION
  • STOCK INFORMATION
  • CORPORATE GOVERNANCE
  • RESOURCES
    • PARTNERS

    Partners

    Current Partners

    Ayala collaborates with companies for the betterment of patients with rare and aggressive cancers.

    Our current partners

    Bristol

    We obtained an exclusive, worldwide license to develop and commercialize AL101 and AL102 from Bristol-Myers Squibb Company, or BMS, in November 2017.

    Read More
    Novartis

    We are collaborating with Novartis International Pharmaceutical Limited, or Novartis, to develop AL102 for the treatment of multiple myeloma, or MM, in combination with Novartis’ B-cell maturation antigen, or BCMA, targeting therapies, since 2018.

    Read More
    Archer

    We are collaborating with ArcherDX to co-develop a suitable diagnostic test that test for all four genes including mutations and fusions, since 2019.

     

    Read More